Abstract: Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
Type:
Grant
Filed:
April 26, 2022
Date of Patent:
May 6, 2025
Assignee:
Vanderbilt University
Inventors:
P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
Abstract: The application relates to a compound of Formula (I?) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutical composition comprising a compound of Formula (I?) or (I), and a method of treating or preventing a disease or disorder regulated by thyroid hormone.
Abstract: Provided are a feed additive composition and a feed composition including the same. The feed additive composition includes ursolic acid and/or maslinic acid, and the feed composition includes the feed additive composition.
Type:
Grant
Filed:
October 8, 2019
Date of Patent:
May 6, 2025
Assignee:
CJ CHEILJEDANG CORPORATION
Inventors:
Young Jung Kim, Je Hun Kim, Sung Hun Kim, Jae Won Kim
Abstract: The invention relates to medical uses of an HDAC inhibitor of the below general formula I, wherein R1 to R7 are as described herein, or a salt or solvate thereof in combination with a CD137 agonist for the treatment of cancer.
Abstract: Disclosed are compounds that possess inhibitory activity against LRRK2. Also disclosed are pharmaceutical compositions containing the compounds and methods of using the compounds to treat diseases and disorders including neurodegenerative diseases and disorders such as Parkinson's disease, and brain cancer (e.g., gliomas and glioblastomas).
Type:
Grant
Filed:
October 16, 2019
Date of Patent:
April 15, 2025
Assignees:
DANA-FARBER CANCER INSTITUTE, INC., VORONOI INC.
Inventors:
Nathanael S. Gray, John Hatcher, Jieun Choi, Hwangeun Choi, Eunhwa Ko, Namdoo Kim
Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
Type:
Grant
Filed:
September 27, 2023
Date of Patent:
April 15, 2025
Assignee:
JANSSEN PHARMACEUTICA NV
Inventors:
Matthew Lucas, Bertrand Le Bourdonnec, Iwona Wrona, Bhaumik Pandya, Parcharee Tivitmahaisoon, Kerem Ozboya, Benjamin Vincent, Daniel Tardiff, Jeff Piotrowski, Eric Solis, Robert Scannevin, Chee-Yeun Chung, Rebecca Aron, Kenneth Rhodes
Abstract: This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
Type:
Grant
Filed:
November 21, 2022
Date of Patent:
April 15, 2025
Assignee:
GENENTECH, INC.
Inventors:
Jason Robert Zbieg, Paul Powell Beroza, Vishal Anil Verma, Bing-Yan Zhu, Ramsay Beveridge, Liang Zhao, Melissa Leblanc, Lisa Marie Barton, Bryan Ka Ip Chan, Samir Bouayad-Gervais, Anwesha Dey, Marie Anne Evangelista, Russell Tyler Smith
Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
Type:
Grant
Filed:
January 19, 2022
Date of Patent:
April 8, 2025
Assignee:
Beam Therapeutics Inc.
Inventors:
Mina Fawzy Shehata, Neeraj Narendra Patwardhan, Gregory Lawrence Hamilton, Cory Dane Sago, Milloni Balwantkumar Chhabra
Abstract: The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of chemotherapy-induced neuropathy, preferably in the treatment and/or prevention of chemotherapy-induced peripheral neuropathy (CIPN) or chemotherapy-induced optic neuropathy.
Type:
Grant
Filed:
January 13, 2017
Date of Patent:
April 8, 2025
Assignee:
DOMPÉ FARMACEUTICI S.P.A.
Inventors:
Laura Brandolini, Pier Adelchi Ruffini, Marcello Allegretti
Abstract: Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.
Abstract: A method for treatment or preventing IgA nephropathy in a subject is provided. The method of treating or preventing IgA nephropathy includes administering a thiol-containing molecule, or a pharmaceutically acceptable salt thereof, to a mammal in need thereof. Also provided is a method and kit for screening candidate therapeutic agents for treating or preventing IgA nephropathy.
Abstract: FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (?)-epicatechin from T. cacao and showed that (?)-epicatechin treatment significantly increases the length of the Fgfr3Y367C/+ femurs comparing to Fgfr3+/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (?)-epicatechin for the treatment of FGFR3-related chondrodysplasias.
Type:
Grant
Filed:
September 8, 2023
Date of Patent:
March 25, 2025
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), UNIVERSIDAD DE GRANADA
Inventors:
Laurence Legeai-Mallet, Antonio Segura Carretero, Maria De La Luz Cadiz Gurrea
Abstract: Hydrophilic Linkers, Drug-Linker compounds, Drug-Ligand Conjugate compounds and Ligand-Linkers and methods of making and using the same are provided.
Type:
Grant
Filed:
July 28, 2023
Date of Patent:
March 25, 2025
Assignee:
Seagen Inc.
Inventors:
Svetlana Doronina, Robert Lyon, Peter Senter
Abstract: The invention provides novel sugar alcohol-based dendrimer-like molecules. These sugar alcohol-based molecules have multiple functional groups that can be used to label, conjugate, and immobilize large amounts of molecules or multiple types of molecules of interest for diagnostic, therapeutic, and research usage. Methods of synthesizing these sugar alcohol-based dendrimer-like molecules and conjugates are also within the scope of the invention.
Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
Type:
Grant
Filed:
October 20, 2023
Date of Patent:
March 25, 2025
Assignee:
VERTEX PHARMACEUTICALS INCORPORATED
Inventors:
Elizabeth Mary Beck, Steven John Durrant, Sarah Skerratt, Robert Pullin, Gorka Etxebarria Jardi, David Matthew Shaw, Nadia M. Ahmad, Christopher Wray, Anisa Nizarali Virani, Kiri North, James Dodd, Michael Edward O'Donnell, Bhairavi Galan, Ronald Marcellus Knegtel, Ewa Iwona Chudyk, Joanne Louise Pinder, Stephen Andrew Thomson, Lidio Marx Carvalho Meireles, Dean Stamos, Yvonne Schmidt, Joseph Pontillo, Sara S. Hadida Ruah, Timothy Donald Neubert, Dennis James Hurley, Jinglan Zhou
Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomersynthesis while maintaining overall yield and purity of a synthesized oligomer.
Type:
Grant
Filed:
February 8, 2021
Date of Patent:
March 25, 2025
Inventors:
Baozhong Cai, Mitchell Martini, Ross Shimabuku, Katie Thomas
Abstract: The present invention discloses a method of treating tumor using a novel pyrimidine derivative. It is demonstrated through the tests on anti-tumor activity at the cellular level (tumor cells expressed with c-Met) that, through the introduction of a chiral structure in the molecule, the introduction of an isotope of hydrogen (deuterium) at the sites that are prone to metabolism in the molecule, and the introduction of atoms or groups such as sulfur, selenium and sulfoxide in the molecule, the compounds of the invention have excellent anti-tumor activities, and the stabilities of the anti-tumor compounds are significantly improved.
Type:
Grant
Filed:
July 19, 2023
Date of Patent:
March 25, 2025
Assignees:
Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangdong CS-Lewwin Drug Research Co., Ltd.
Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of treatment for various diseases or conditions, such as cancer. In one aspect, the method comprises the treatment of metastatic cancers. Compounds and methods provided herein are also used for the treatment of diseases such as inflammatory disease, cardiovascular disease, autoimmune disease, and dry eye syndrome. Further provided herein are dietary supplement formulations and methods for supporting a healthy lifestyle.
Type:
Grant
Filed:
May 15, 2019
Date of Patent:
March 25, 2025
Inventors:
Yu-Hsin Tom Lin, Cheng-Chi Irene Wang, Jason Olejniczak
Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
Type:
Grant
Filed:
September 6, 2024
Date of Patent:
March 18, 2025
Assignee:
Novartis AG
Inventors:
Simone Bonazzi, Jennifer Stroka Cobb, Natalie Alysia Dales, Matthew James Hesse, Rama Jain, John Ryan Kerrigan, Hasnain Ahmed Malik, James R Manning, Pamela Yf Ting
Abstract: The present invention provides a cyclobutyl dihydroquinoline sulfonamide compound of Formula (I), an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.
Type:
Grant
Filed:
June 10, 2021
Date of Patent:
March 4, 2025
Assignee:
AMGEN INC.
Inventors:
Benjamin C Milgram, Isaac E Marx, Haoxuan Wang, Alan H Cherney